Michael Ellis
About Michael Ellis
Michael Ellis is the Senior Vice President, Head of Small Molecule Drug Discovery at Bristol Myers Squibb and a Board Observer at Octant.
Company
Michael Ellis is currently working at Bristol Myers Squibb in Cambridge, Massachusetts, United States. He holds the position of Senior Vice President, Head of Small Molecule Drug Discovery. Additionally, he is serving as a Board Observer at Octant.
Title
Michael Ellis is the Senior Vice President, Head of Small Molecule Drug Discovery at Bristol Myers Squibb. His role involves overseeing small molecule drug discovery efforts within the company.
Professional Background
Michael Ellis has extensive experience in the pharmaceutical industry, having held key positions at various organizations. He was Vice President at Bristol Myers Squibb from 2021 to 2022 and Executive Director from 2019 to 2021. Prior to that, he worked at Celgene as Executive Director in 2019 and Senior Director from 2018 to 2019. His career began at Merck, where he held several roles including Director, Principal Scientist, and Senior Research Chemist from 2009 to 2018.
Education and Expertise
Michael Ellis completed his Ph.D. in Chemistry at the University of North Carolina at Chapel Hill from 2002 to 2007, following a B.S. in Chemistry from Wake Forest University (1998-2002). He has also pursued executive education programs at Wharton and Duke University. His postdoctoral research was funded by the NIH at the University of California, Irvine, focusing on medicinal chemistry.
Achievements
Michael Ellis received the American Chemical Society (ACS) Young Investigator’s Award in 2016. He has served as the chair of the 2019 Boston Symposium on Organic & Bioorganic Chemistry and the 2023 Medicinal Chemistry Gordon Research Conference. Additionally, he is an active member of the ACS Executive Committee as Alternate Councilor and a section editor for Medicinal Chemistry Reviews. His contributions include the discovery of clinical assets, development candidates, and enabling tools and platforms.